<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Tocilizumab is a humanized monoclonal antibody against IL-6 receptor cytokine. Tocilizumab targets both membrane and soluble-bound IL-6 receptors. This mAb is used for the treatment of COVID-19 patients [
 <xref ref-type="bibr" rid="CR47">47</xref>]. It is shown that the IL-6 level is considerably high in severe COVID-19 cases. Treatment of 21 severe COVID-19 cases with tocilizumab indicated that using this monoclonal antibody is an effective treatment and well tolerated in these patients. In the preprinted study, tocilizumab caused body temperature and CRP returned to the normal levels and improved lung function [
 <xref ref-type="bibr" rid="CR48">48</xref>]. There are also many registered clinical trials on efficiency and safety of tocilizumab for the treatment of COVID-19 (Table 
 <xref rid="Tab1" ref-type="table">1</xref>).
</p>
